Drugs / BMS-986196
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06034899 | Sep → Nov 2023 | — | Bristol-Myers Squibb | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT05981963 | Aug → Oct 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05891262 | Jun → Aug 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT05852769 | May → Aug 2023 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1 | NCT04882150 | May 2021 → Jun 2022 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-986196 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05981963 ↗ |
| Known as | [14C]-BMS-986196 | “Pharmacokinetics, Metabolism, and Excretion of Orally Administered 60 mg BMS-986196, Including Radioactively Labeled [14C]-BMS-986196, in Healthy Male Participants” NCT05981963 ↗ |
| Route | Oral | “Orally Administered 60 mg BMS-986196” NCT05981963 ↗ |